Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer.

导出原文传递

翻译打印收藏纠错

作者： Peter A,Kaufman ^[1] ; Hans,Wildiers ^[2] ; Gilles,Freyer ^[3] ; Margaret,Kemeny ^[4] ; Anthony,Gonçalves ^[5] ; Guy,Jerusalem ^[6] ; Alison,Stopeck ^[7] ; Nandagopal,Vrindavanam ^[8] ; Florence,Dalenc ^[9] ; Nuwan,Nanayakkara ^[10] ; Benjamin,Wu ^[11] ; Cheryl A,Pickett ^[12]

作者单位： Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, NH. Electronic address: Peter.a.kaufman@dartmouth.edu. ^[1] KU Leuven and Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium. ^[2] Medical Oncology, HCL Cancer Institute and Lyon 1 University, Lyon, France. ^[3] Queens Cancer Center, Queens, NY. ^[4] Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France. ^[5] Department of Medical Oncology, CHU Sart Tilman Liège and Liège University, Liège, Belgium. ^[6] Division of Hematology/Oncology, Stony Brook Cancer Center, Stony Brook, NY. ^[7] Department of Clinical Research, Signal Point Clinical Research Center, LLC, Middletown, OH. ^[8] Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France. ^[9] Quintiles, San Diego, CA. ^[10] Department of Medical Sciences, Amgen Inc, Thousand Oaks, CA. ^[11] Department of Clinical Development, Amgen Inc, Thousand Oaks, CA. ^[12]

关键词 AMG 386 Angiogenesis Angiopoietin HER2 positive